Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)37.70
  • Today's Change-1.05 / -2.71%
  • Shares traded3.29m
  • 1 Year change+45.00%
  • Beta2.6219
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform1
Hold3
Sell0
Strong Sell0

Share price forecast in CNY

The 6 analysts offering 12 month price targets for Everest Medicines Ltd have a median target of 25.92, with a high estimate of 43.94 and a low estimate of 24.46. The median estimate represents a -31.26% decrease from the last price of 37.70.
High16.5%43.94
Med-31.3%25.92
Low-35.1%24.46

Earnings history & estimates in CNY

Everest Medicines Ltd reported annual 2023 losses of -2.39 per share on Mar 27, 2024.
Average growth rate-1,261.83%
More ▼

Revenue history & estimates in CNY

Everest Medicines Ltd had revenues for the full year 2023 of 125.93m. This was 884.46% above the prior year's results.
Average growth rate+12,236.67%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.